An Amphotericin B Derivative Equally Potent to Amphotericin B and with Increased Safety

一种与两性霉素 B 具有同等效力且安全性更高的两性霉素 B 衍生物

阅读:6
作者:Armando Antillón, Alexander H de Vries, Marcel Espinosa-Caballero, José Marcos Falcón-González, David Flores Romero, Javier González-Damián, Fabiola Eloísa Jiménez-Montejo, Angel León-Buitimea, Manuel López-Ortiz, Ricardo Magaña, Siewert J Marrink, Rosmarbel Morales-Nava, Xavier Periole, Jorge Reyes

Abstract

Amphotericin B is the most potent antimycotic known to date. However due to its large collateral toxicity, its use, although long standing, had been limited. Many attempts have been made to produce derivatives with reduced collateral damage. The molecular mechanism of polyene has also been closely studied for this purpose and understanding it would contribute to the development of safe derivatives. Our study examined polyene action, including chemical synthesis, electrophysiology, pharmacology, toxicology and molecular dynamics. The results were used to support a novel Amphotericin B derivative with increased selectivity: L-histidine methyl ester of Amphotericin B. We found that this derivative has the same form of action as Amphotericin B, i.e. pore formation in the cell membrane. Its reduced dimerization in solution, when compared to Amphotericin B, is at least partially responsible for its increased selectivity. Here we also present the results of preclinical tests, which show that the derivative is just as potent as Amphotericin B and has increased safety.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。